BURNABY, BC, Sept. 7 /CNW/ - Welichem Biotech Inc. ("WBI" or the
"Company") (TSX-V: WBI - News) is very pleased to report that the Phase I
Clinical Trials of the Company's anti-psoriasis drug candidate, WBI-1001, are
running as planned in Montreal, Quebec. The trials consist of six separate
cohorts. All six patients in Cohort I have been treated with WBI-1001 for at
least fourteen days and none has experienced any adverse side effects.
Patients for Cohor
